Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.76 |
| ▸ | RAB9A | P51151 | 9/20 | 0.76 |
| ▸ | MAPT | P10636 | 8/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 7/20 | 0.76 |
| ▸ | PKM | P14618 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | CASP3 | P42574 | 1/20 | 0.76 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.76 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.76 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7540052 | 0.92 | MAPK1 (0.84) | MEN1KMT2ARAB9AMAPTMAPK1 | |
| SCHEMBL206240 | 0.91 | MEN1 (0.73) | MEN1KMT2ARAB9AMAPTMAPK1 | |
| Bromide SCHEMBL7691671 | 0.91 | MAPK1 (0.82) | MEN1KMT2ARAB9AMAPTMAPK1 | |
| SCHEMBL28319654 | 0.89 | MEN1 (0.74) | MEN1KMT2ARAB9AMAPTMAPK1 | |
| SCHEMBL206486 | 0.87 | MEN1 (0.76) | MEN1KMT2ARAB9AMAPTMAPK1 | |
| SCHEMBL996232 | 0.87 | RAB9A (1.00) | MEN1KMT2ARAB9AMAPTMAPK1 | |
| SCHEMBL18769586 | 0.86 | MEN1 (0.79) | MEN1KMT2ARAB9AMAPTMAPK1 | |
| SCHEMBL22560267 | 0.86 | MAPK1 (1.00) | MEN1KMT2ARAB9AMAPTMAPK1 | |
| SCHEMBL12157931 | 0.86 | MEN1 (1.00) | MEN1KMT2ARAB9AMAPTMAPK1 | |
| SCHEMBL12297696 | 0.85 | CFTR (0.70) | MEN1KMT2ARAB9AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | claimed |
| EP-1926719-B1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | disclosed |
| EP-1926719-B1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | disclosed |
| US-9388175-B2 | 2-aniline-4-aryl substituted thiazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-07-12 | — | — | US | disclosed |
| US-9388175-B2 | 2-aniline-4-aryl substituted thiazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-07-12 | — | — | US | disclosed |
| US-9388175-B2 | 2-aniline-4-aryl substituted thiazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-07-12 | — | — | US | disclosed |
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-03 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | CHRNA4, CHRNA5, CHRNA7 | MEN1 3692/4885KMT2A 1603/4885RAB9A 3437/4885 |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | VHL, TP53, BECN1 | MEN1 3092/4885KMT2A 2132/4885RAB9A 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.